Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-G2-044 in Platinum-Resistant Ovarian Cancer
NCT07109414Phase 3Active, not recruiting
- Sponsor
- Novita Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prilukae in ovarian cancer (7 arms), sponsored by Novita Pharmaceuticals. Primary endpoints: Number of participants with Dose Limiting Toxicities, Overall Response Rate and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
Prilukae
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07109414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109414.